Precision peptide research for the next decade of biology.
Ceretropic Labs develops and distributes high-purity research peptides for laboratory applications across Europe. We focus on compounds with meaningful clinical signal and underserved supply.
Research peptides, done to a clinical standard.
Three problems define the research peptide market: purity claims nobody verifies, formulation shortcuts that degrade product before it reaches the lab, and supply inconsistency that breaks research continuity. Ceretropic Labs addresses each one.
Verified purity
Every batch undergoes HPLC analysis with the certificate attached to the vial lot number. No batch ships without the data available on request.
Stabilized formulation
Phosphate buffer at pH 6.5, phenol preservative, polysorbate stabilizer. The same formulation platform used in branded GLP-1 pens. Extended post-reconstitution stability compared to plain bacteriostatic water.
Batch consistency
Single synthesis partner, standardized QC protocol, lot numbering that traces back to specific production runs. Research continuity across multiple orders.
Four focus categories, one quality standard.
Regenerative
Copper-peptide complexes and tissue-repair compounds. First launch: GHK-Cu at pharmaceutical-grade formulation standards.
Read more →Metabolic
GLP-1 class compounds including retatrutide, tirzepatide, and semaglutide. Launch target: Q1 2027, distribution through verified partners.
Read more →Longevity
Mitochondrial peptides (MOTS-c, SS-31), telomere-pathway compounds (Epithalon), and senolytic research tools.
Read more →Healing & recovery
BPC-157, TB-500, and the classic healing stack with full documentation on reconstitution and storage.
Read more →We work through specialised regional partners.
Ceretropic Labs product reaches researchers through distribution partners who handle local-market logistics, documentation, and language support. Current and upcoming partners:
- ghkcu.rs — Serbian market, GHK-Cu Official formulation. Active since Q4 2026.
- Additional regional partners — in evaluation for Croatian, Slovenian, and broader EU markets through 2027.